Bridget M. Ahmann, a partner in the Faegre & Benson LLP litigation practice, will be a speaker at the Hamline Law Review 2009 Symposium, "The Food, Drug, and Cosmetic Act—Searching for the Crossroads of Safety and Innovation," to be held April 3 at the Hamline University Klas Center in St. Paul.
The symposium will examine recent cases involving federal preemption of state tort claims against medical device manufacturers that make FDA-approved devices—including Wyeth v. Levine and the 2008 U.S. Supreme Court decision in Riegel v. Medtronic. Speakers will also address legislation relevant to these cases, including the FDCA's drug provisions and Congress's decision to introduce the Medical Device Safety Act of 2008.
Ahmann will speak on the topic "Name Brand Exposure for Generic Drug Use: Prescription for Liability." The presentation will address an innovator's liability for generic drugs, including the recent Conte decision from the California appellate court.
Ahmann focuses her practice on product liability and mass torts, with a particular emphasis in pharmaceutical and medical device litigation. She has been involved in a wide variety of class action, multidistrict and mass tort litigation including anti-psychotic medication, antidepressants, hormone therapy, diet drugs, silicone gel breast implants, orthopedic implants, latex gloves, vaccines, blood factor concentrates and contaminated food products.Faegre & Benson is a sponsor of the Hamline Law Review 2009 Symposium. For a complete program and registration information, please click here.